Histoplasmosis
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Histoplasmosis is an emerging landscape with 13 programs across 8 companies. The most active players are Regeneron, Roche, Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. 1 therapy is approved with 6 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Regeneron
1 program
Roche
1 program
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
1 program
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
1 program
Sebela Pharmaceuticals Development LLC
1 program
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
1 program
Pipeline
Programs by Phase
Amphotericin B
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Itraconazole
Sebela Pharmaceuticals Development LLC
Posaconazole
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
L-Amb Standard Dose
Federal University of Health Science of Porto Alegre
Lamb B
University of Minnesota
Analysis
Modality Breakdown
87%
Small molecule
13 of 15 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 15 classified programs, each share of the total. Modality classified for 94% of 16 pipeline programs.
Analysis
Trial Status
14
clinical trials
Clinical Trials
Trial Activity
14 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)